Evaluation of a Streptococcus thermophilus strain with innate anti-inflammatory properties as a vehicle for IL-10 cDNA delivery in an acute colitis model

Cytokine

Volumn 73, Issue 2, 2015, Pages 177-183

  del Carmen, Silvina ^a   Miyoshi, Anderson ^b   Azevedo, Vasco ^b   de Moreno de LeBlanc, Alejandra ^a   LeBlanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Anti inflammatory; DNA delivery; Inflammatory bowel disease; Interleukin 10; Streptococcus thermophilus

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENTARY DNA; INTERLEUKIN 10; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; STREPTOCOCCUS THERMOPHILUS; ANIMAL; BODY FLUID; BODY WEIGHT; CACO 2 CELL LINE; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INTESTINE; LIVER; METABOLISM; MICROBIOLOGY; PATHOLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; MUS; STREPTOCOCCUS THERMOPHILUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BODY FLUIDS; BODY WEIGHT; CACO-2 CELLS; COLITIS; DISEASE MODELS, ANIMAL; DNA, COMPLEMENTARY; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-10; INTESTINES; LIVER; MICE; STREPTOCOCCUS THERMOPHILUS;

EID: 84924739041     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.02.020     Document Type: Article

References (30)

1. LeBlanc J.G., de Moreno de LeBlanc A. Crohn's disease: etiology, diagnosis and treatment options 2013, Nova Science Publishers, Inc., Hauppauge, NY, USA. 1st ed.
2. Neurath M.F. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014, 14:329-342.
3. de Moreno de LeBlanc A., del Carmen S., Zurita-Turk M., Santos Rocha C., van de Guchte M., Azevedo V., et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterology. 2011, 2011:1-11.
4. Tilg H., van Montfrans C., van den Ende A., Kaser A., van Deventer S.J., Schreiber S., et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002, 50:191-195.
5. Schreiber S., Fedorak R.N., Nielsen O.H., Wild G., Williams C.N., Nikolaus S., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology 2000, 119:1461-1472.
6. del Carmen S., de Moreno de LeBlanc A., Perdigon G., Bastos Pereira V., Miyoshi A., Azevedo V., et al. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis Using a murine Model of Crohn's disease. J Mol Microbiol Biotechnol 2012, 21:138-146.
7. del Carmen S., Rosique R.M., Saraiva T., Zurita-Turk M., Miyoshi A., Azevedo V., et al. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. J Clin Gastroenterol 2014, 48. S12-S7.
8. Huyghebaert N., Vermeire A., Neirynck S., Steidler L., Remaut E., Remon J.P. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10. Eur J Pharm Biopharm 2005, 60:349-359.
9. Lindsay J., Van Montfrans C., Brennan F., Van Deventer S., Drillenburg P., Hodgson H., et al. IL-10 gene therapy prevents TNBS-induced colitis. Gene Ther 2002, 9:1715-1721.
10. Lindsay J., Sandison A., Cohen P., Brennan F., Hodgson H. IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis. Dig Dis Sci 2004, 49:1327-1334.
11. Nakase H., Okazaki K., Tabata Y., Ozeki M., Watanabe N., Ohana M., et al. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther 2002, 301:59-65.
12. LeBlanc JG, Carmen Sd, Lima FA, Turk MZ, Miyoshi A, Azevedo V, et al. Prospective uses of genetically engineered lactic acid bacteria for the prevention of inflammatory bowel diseases. In: Gastrointestinal Disorders; 2011.
13. del Carmen S., de Moreno A., de LeBlanc A., Miyoshi V., Azevedo L.G., Bermúdez-Humarán P.Langella., et al. Anti-inflammatory properties of genetically modified lactic acid bacteria. Bioactive foods in chronic disease states - arthritis and related inflammatory and autoimmune diseases 2012, Elsevier, Oxford. R.R. Watson (Ed.).
14. LeBlanc J.G., Aubry C., Cortes-Perez N.G., de Moreno de LeBlanc A., Vergnolle N., Langella P., et al. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett 2013, 344:1-9.
15. Schotte L., Steidler L., Vandekerckhove J., Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 2000, 27:761-765.
16. Steidler L., Hans W., Schotte L., Neirynck S., Obermeier F., Falk W., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
17. Steidler L., Neirynck S., Huyghebaert N., Snoeck V., Vermeire A., Goddeeris B., et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotech 2003, 21:785-789.
18. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-759.
19. Guimaraes V., Innocentin S., Chatel J.M., Lefevre F., Langella P., Azevedo V., et al. A new plasmid vector for DNA delivery using lactococci. Genet Vaccines Ther 2009, 7:4.
20. del Carmen S., Zurita-Turk M., Alvarenga Lima F., Coelho dos Santos J.S., Leclercq S.Y., Chatel J.-M., et al. A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur J Inflammation 2013.
21. Zurita-Turk M., del Carmen S., Santos A.C., Pereira V.B., Cara D.C., Leclercq S.Y., et al. Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis. BMC Biotechnol 2014, 14:73.
22. del Carmen S., de LeBlanc A.d.M., Martin R., Chain F., Langella P., Bermúdez-Humarán L.G., et al. Genetically engineered immunomodulatory Streptococcus thermophilus producing antioxidant enzymes show enhanced anti-inflammatory activities. Appl Environ Microbiol 2014, 80:869-877.
23. del Carmen S., de Moreno de LeBlanc A., Perdigon G., Bastos Pereira V., Miyoshi A., Azevedo V., et al. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn's disease. J Mol Microbiol Biotechnol 2011, 21:138-146.
24. Benbouziane B., Ribelles P., Aubry C., Martin R., Kharrat P., Riazi A., et al. Development of a stress-inducible controlled expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 2013, 168:120-129.
25. Yao J., J-y Wang., Lai M.-G., Y-x Li., H-m Zh.u., R-y Shi., et al. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Mol Pharm 2011, 8:488-497.
26. Bermúdez-Humarán L.G., Kharrat P., Chatel J.-M., Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011, 10:S4.
27. Pontes D.S., De Azevedo M.S.P., Chatel J.-M., Langella P., Azevedo V., Miyoshi A. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr Purif 2011, 79:165-175.
28. Hanson M.L., Hixon J.A., Li W., Felber B.K., Anver M.R., Stewart C.A., et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 2014, 146(210-21):e13.
29. Dibra D., Li S. The cell-to-cell coordination between activated T cells and CpG-stimulated macrophages synergistically induce elevated levels of IL-10 via NF-kappaB1, STAT3, and CD40/CD154. Cell Commun Signaling: CCS 2013, 11:95.
30. Mitra A., Satelli A., Yan J., Xueqing X., Gagea M., Hunter C.A., et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology (Baltimore, MD) 2014, 60:2027-2039.